Sequential empagliflozin, linagliptin diabetes Tx effective

January 4, 2017

(HealthDay)—After metformin failure, sequential treatment escalation with empagliflozin and linagliptin is an effective diabetes treatment option due to additive effects on postprandial glucose control, according to a study published online Dec. 23 in Diabetes, Obesity and Metabolism.

Thomas Forst, M.D., from Johannes Gutenberg University in Mainz, Germany, and colleagues conducted an open-label trial ( period [TP] 1) in which 44 patients with type 2 received 25 mg empagliflozin for one month. In TP 2, patients were randomized to a double-blind add-on therapy with linagliptin 5 mg or placebo for another month. A standardized liquid meal test and an intravenous glucose challenge were used to assess alpha- and beta-cell function.

The researchers found that in TP 1, empagliflozin reduced fasting and postprandial plasma , correlating with a significant reduction in postprandial insulin levels and an improvement in the conversion rate of proinsulin. In TP 2, addition of linagliptin further improved postprandial glucose levels, most likely due to a marked reduction in postprandial glucagon concentrations. The insulin response to an intravenous glucose load improved in both TPs.

"After metformin failure, sequential treatment escalation with empagliflozin and linagliptin is an attractive treatment option due to additive effects on postprandial control, most probably mediated by complementary effects on alpha- and beta-cell function," the authors write.

Explore further: GLP-1 receptor agonists can manage postprandial glucose

More information: Full Text (subscription or payment may be required)

Related Stories

GLP-1 receptor agonists can manage postprandial glucose

November 17, 2015

(HealthDay)—Glucagon-like peptide 1 (GLP-1) receptor agonists appear beneficial for postprandial glucose management in type 2 diabetes, according to a report published in the October issue of Clinical Diabetes.

Bile acid sequestrant reduces glucose concentration in T2DM

January 30, 2013

(HealthDay)—For patients with type 2 diabetes taking metformin monotherapy, the bile acid sequestrant colesevelam reduces fasting and postprandial glucose concentrations without any effects on insulin concentration, secretion, ...

Postprandial hyperglycemia linked to CVD incidence in T2DM

December 28, 2016

(HealthDay)—For patients with type 2 diabetes, postprandial hyperglycemia is associated with incidence of cardiovascular disease (CVD) and all-cause mortality, independently of the mean glycated hemoglobin (HbA1c) level, ...

Fat, protein impact postprandial glucose excursion in T1DM

December 19, 2013

(HealthDay)—For children with type 1 diabetes using intensive insulin therapy (IIT), high-fat (HF) and high-protein (HP) meals increase glucose excursions, with an additive effect observed, according to a study published ...

The Homburg Cream and Sugar study

August 29, 2011

The Homburg Cream and Sugar (HCS) study was designed to determine whether the measurement of postprandial triglyceride in addition to the assessment of glucose tolerance and traditional risk factors might improve the prediction ...

Recommended for you

Designing better drugs to treat type 2 diabetes

May 18, 2017

Research led by the University of Adelaide is paving the way for safer and more effective drugs to treat type 2 diabetes, reducing side effects and the need for insulin injections.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.